{"id":55694,"date":"2026-01-29T13:43:28","date_gmt":"2026-01-29T05:43:28","guid":{"rendered":"https:\/\/flcube.com\/?p=55694"},"modified":"2026-01-29T13:43:29","modified_gmt":"2026-01-29T05:43:29","slug":"seamless-therapeutics-partners-with-eli-lilly-on-1-12b-hearing-loss-recombinase-deal","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55694","title":{"rendered":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal"},"content":{"rendered":"\n<p><strong>Seamless Therapeutics<\/strong>, a Germany\u2011based gene editing company, announced a <strong>global strategic research collaboration and license agreement<\/strong> with <strong>Eli Lilly<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/LLY:NYSE\">NYSE:\u202fLLY<\/a>) to develop and commercialize <strong>recombinase therapies for hearing loss<\/strong> using its proprietary <strong>programmable recombinase platform<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-deal-structure-amp-strategic-terms\">Deal Structure &amp; Strategic Terms<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Companies<\/strong><\/td><td>Seamless Therapeutics \/ Eli Lilly (NYSE:\u202fLLY)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Global strategic research collaboration and license<\/td><\/tr><tr><td><strong>Technology<\/strong><\/td><td>Programmable recombinase platform<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Hearing loss (gene mutation correction)<\/td><\/tr><tr><td><strong>Responsibilities<\/strong><\/td><td>Seamless: Design\/program site\u2011specific recombinases; Lilly: Preclinical, clinical, commercialization<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + committed research funding + milestones <strong>&gt;USD\u202f1.12\u202fbillion<\/strong> + tiered royalties<\/td><\/tr><tr><td><strong>Exclusivity<\/strong><\/td><td>Eli Lilly obtains exclusive license to programmed recombinases<\/td><\/tr><tr><td><strong>Strategic Value<\/strong><\/td><td>First major recombinase partnership for hearing loss; validates Seamless\u2019 platform<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-technology-profile-amp-innovation\">Technology Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Mechanism:<\/strong> <strong>Programmable recombinases<\/strong> induce precise DNA recombination to correct defined gene mutations causing hereditary hearing loss<\/li>\n\n\n\n<li><strong>Platform Advantage:<\/strong> Enables <strong>site\u2011specific gene editing<\/strong> without double\u2011stranded DNA breaks, potentially reducing off\u2011target effects versus CRISPR\u2011based approaches<\/li>\n\n\n\n<li><strong>Target Scope:<\/strong> Addresses monogenic forms of hearing loss affecting an estimated <strong>1\u20132\u202fmillion patients<\/strong> globally<\/li>\n\n\n\n<li><strong>Pipeline Logic:<\/strong> Focuses on well\u2011characterized mutations (e.g., GJB2, OTOF) where single\u2011correction events could restore normal auditory function<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Genetic Hearing Loss Market:<\/strong> Global market projected to exceed <strong>$5\u202fbillion<\/strong> :by 2035 as gene therapies mature; no approved curative treatments exist today<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> <strong>$1.12\u202fbillion<\/strong> in milestones plus royalties positions Seamless for significant long\u2011term value creation; analysts estimate peak sales potential of <strong>$2\u20133\u202fbillion<\/strong> :for successful recombinase therapy<\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Competes with <strong>CRISPR Therapeutics<\/strong>, <strong>Editas<\/strong>, and <strong>Regeneron<\/strong> in genetic hearing loss; Seamless\u2019 recombinase approach offers distinct mechanistic differentiation<\/li>\n\n\n\n<li><strong>Strategic Fit:<\/strong> Expands Lilly\u2019s <strong>gene therapy footprint<\/strong> beyond diabetes and oncology, leveraging its CNS and rare disease commercial infrastructure<\/li>\n\n\n\n<li><strong>Clinical Timeline:<\/strong> Investigational New Drug (IND) application expected <strong>2027<\/strong>; Phase\u202fI data anticipated <strong>2028<\/strong><\/li>\n\n\n\n<li><strong>Manufacturing:<\/strong> Lilly to leverage its biologics production expertise for recombinase protein manufacturing and AAV delivery vector production<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding development timelines, clinical outcomes, and revenue potential for the recombinase hearing loss program. Actual results may differ due to preclinical and clinical risks, regulatory pathways, and competitive dynamics in the gene editing space.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55762,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[199,911,4579],"class_list":["post-55694","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-eli-lilly","tag-nyse-lly","tag-seamless-therapeutics"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55694\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal\" \/>\n<meta property=\"og:description\" content=\"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55694\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T05:43:28+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T05:43:29+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal\",\"datePublished\":\"2026-01-29T05:43:28+00:00\",\"dateModified\":\"2026-01-29T05:43:29+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694\"},\"wordCount\":369,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2901.webp\",\"keywords\":[\"Eli Lilly\",\"NYSE: LLY\",\"Seamless Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55694#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55694\",\"name\":\"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2901.webp\",\"datePublished\":\"2026-01-29T05:43:28+00:00\",\"dateModified\":\"2026-01-29T05:43:29+00:00\",\"description\":\"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55694\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55694#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal - Insight, China&#039;s Pharmaceutical Industry","description":"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55694","og_locale":"en_US","og_type":"article","og_title":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal","og_description":"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.","og_url":"https:\/\/flcube.com\/?p=55694","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T05:43:28+00:00","article_modified_time":"2026-01-29T05:43:29+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55694#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55694"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal","datePublished":"2026-01-29T05:43:28+00:00","dateModified":"2026-01-29T05:43:29+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55694"},"wordCount":369,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55694#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","keywords":["Eli Lilly","NYSE: LLY","Seamless Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55694#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55694","url":"https:\/\/flcube.com\/?p=55694","name":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55694#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55694#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","datePublished":"2026-01-29T05:43:28+00:00","dateModified":"2026-01-29T05:43:29+00:00","description":"Seamless Therapeutics, a Germany\u2011based gene editing company, announced a global strategic research collaboration and license agreement with Eli Lilly (NYSE:\u202fLLY) to develop and commercialize recombinase therapies for hearing loss using its proprietary programmable recombinase platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55694#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55694"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55694#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","width":1080,"height":608,"caption":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55694#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Seamless Therapeutics Partners with Eli Lilly on $1.12B Hearing Loss Recombinase Deal"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55694","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55694"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55694\/revisions"}],"predecessor-version":[{"id":55761,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55694\/revisions\/55761"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55762"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55694"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55694"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55694"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}